RecruitingNCT06827353

Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency

Studying Malignant epithelial tumor of ovary

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Centre Hospitalier Universitaire de Nīmes
Principal Investigator
soufyan annakib, M.D.
Intervention
maintenance therapy with bevacizumab(drug)
Enrollment
300 enrolled
Eligibility
18 years · FEMALE
Timeline
20202025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06827353 on ClinicalTrials.gov

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

See all trials for Malignant epithelial tumor of ovary

← Back to all trials